Comparative Clinical Performance of MAST URI^®Plates and Disc Diffusion

Nanomix eLAB^® for mulitplex detection of Procalcitonin, CRP and Lactate in 12 minutes.

New addition to the MASTDISCS^® range – Ceftobiprole 5µg available now!

New Approved CLSI Criteria for Bovine Mastitis Pathogens

Welcome to Mast Group

The parent company, Mast Group Ltd, has corporate headquarters in Bootle near Liverpool, UK. Mast Group Ltd. also has Subsidiary companies in Reinfeld, Germany (Mast Diagnostica GmbH) and Amiens, France (Mast Diagnostic).

Company Details

Latest News

07 December 2022

Comparative clinical performance of MAST URI^®Plates and Disc Diffusion

MAST URI^®Plates are made to the current EUCAST breakpoints for urinary tract infections.

25 November 2022

Sepsis & Critical Care Management

MAST Group is excited to announce a multi-region distribution agreement with Nanōmix Corporation, a leader in the development of mobile point-of-care (POC) diagnostics, to distribute the Nanōmix eLab^® system in the United Kingdom, Germany, France, Ireland and South Africa.

14 November 2022

World Antimicrobial Awareness Week: 18 - 24 November

Will you 'go blue' for World Antimicrobial Awareness Week this week?

Comparative Clinical Performance of MAST URI® Plates and Disc Diffusion

Sepsis & Critical Care Management:

Nanomix eLAB® for mulitplex detection of Procalcitonin, CRP and Lactate in 12 minutes.

New addition to the MASTDISCS® range – Ceftobiprole 5µg available now!

New Approved CLSI Criteria for Bovine Mastitis Pathogens

MAST URI®SYSTEM

AST

AMR

Molecular

Culture Media and Supplements

ID and Detection

Pharmaceutical

Immunology

Veterinary

Miscellaneous

Specialist Biochemistry

Critical Point of Care